https://www.selleckchem.com/pr....oducts/trastuzumab.h
407, P = 0.008). Tartrate-resistant acid phosphatase (TRACP-5b) was found to be the most accurate marker to predict DAAH with AUC of 0.750 (95% CI; 0.546-0.954, P = 0.02) and the optimal cut-off level was 670 mU/mL with sensitivity; 0.727 and specificity; 0.733. BMD significantly increased by 5.9 ± 1.7% (P = 0.01) at LS and 4.2 ± 1.5% (P = 0.04) at FN at 24 months. In hemodialysis patients, high bone turnover was an independent risk factor for the Ca declines induced by denosumab. Denosumab significantly increased BMD at LS and FN o
Like
Comment
Share
